BIP Central Venous Catheter

Similar documents
multicath & multistar

Fighting Hospital Acquired Infection

Anti-Infective Solutions

HarnessingTaurolidine Technology

ARROW EDGE. Antegrade-tunneled chronic hemodialysis catheter

Palindrome Precision Chronic Dialysis Catheter Family

Comfort your patient deserves. Strength you demand.

lifecath PICC & maxflo CT

Microbiology for Oral and Topical Products - The basics Scott Colbourne Business Manager NSW ALS Food & Pharmaceutical

Designed To Prevent Infections

Anti-Infective Solutions

HarnessingTaurolidine Technology

How to Prevent Central Line- Associated Sepsis in the NICU

55 Industrial Park Road Boothbay, ME USA

TIPS AND TRICKS OF CENTRAL LINE CARE

SecuSan The new hygiene standard Clinically tested

Improving patient outcomes with proper IV securement

POLYSITE Low Profile Hybrid Ports. Comfort your patient deserves. Strength you demand.

The Effects of Superparamagnetic Iron Oxide Nanoparticles on Biofilm. Thousand Oaks High School AP Research STEM

Preventing Peripheral IV Failure: The Next Big Thing In Vascular Access Adjunct Products

Antimicrobial Surfaces to Prevent Healthcare-Associated Infection

Standard and Directives on Medical Devices

ONAMER M. PRESERVATIVE and ANTIMICROBIAL ONAMER

510(k) Summary. 510(k) Number: K Summary Prepared: August 31, 2017

A Bayesian Belief Network Model for Risk of Vascular Catheter-Associated Infection

D-Stat Dry Topical Hemostat Proven to Reduce Time-to-Hemostasis 1,2

CATHETER SURFACE INTERACTIONS WITH HUMAN TISSUE. Anthony Chesna Anthony DiBella

NIMBUS The Next Generation in Antimicrobial Protection. October, 2010

Research Interests: Smart Bandage Systems

Infection Prevention with Certofix protect. Technical brochure of a non-leaching central venous catheter. Patient Access

Comparison of the speed of kill of pathogenic bacteria using ACTICOAT and AQUACEL Ag analysed using Confocal Laser Scanning Microscopy

Description. Used materials. Warnings and precautions

smart antimicrobial additive we will work with you to create unique antimicrobial solutions to fit your product needs PROVEN ANTIMICROBIAL ACTIVITY

TECHNICAL DATA SHEET BD Emerald Syringe with and without needle Sterile, Single Use, Latex free

Teleflex Incorporated (NYSE: TFX) Investor Presentation

FACTSHEET. Introduction. Antibodies ALTERNATIVES TO ANTIBIOTICS

COATING SYSTEMS BIOLINE COATING

Biocompatibility: a risk based approach

WHITE PAPER MEDICAL-GRADE SILICONE LUBRICANTS FOR MEDICAL DEVICES

The Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2

All you need to know!

Int.J.Curr.Microbiol.App.Sci (2014) 3(10)

Polidocanol Endovenous Microfoam (PEM) Comprehensive Treatment for Great Saphenous Vein System (GSV) Incompetence

INTRODUCTION Sanitization sterilization Antibiotics Bactericidal Bacteriostatic Antiseptics disinfectants

GENOMERA TM MRSA/SA PRODUCTS A NEW ERA IN DIRECT MRSA DNA TESTING. Bringing genetic MRSA results in less than 1 hour!

NEW DRUG FORMULATIONS TO BOOST FIGHT AGAINST RESPIRATORY ILLNESSES AND ANTIBIOTIC-RESISTANT SUPERBUGS

DRUG REGISTRATION REGULATION

Marvelous (MRVLS) Elcam Medical s New & Innovative Minimal Residual Volume Luer Activated Stopcock

Optimizing Bacterial Adhesion to a Microfluidic Platform for Monitoring Bacterial Biofilm Growth

Silver Ion Antimicrobial Agents in the Battle Against Hospital Acquired Infections

What have we learnt from clinical trials in invasive candidiasis?

DSM Non-Biofouling Coatings: A Stealth Approach to Fighting Biofilms BioInterface 18 th October 2009 Atlanta, GA.

Bionector The 7 Day/150 Access, Closed, Needle-Free, IV Access System

EVIDENCE-BASED PAPER - CONTINUOUS AND INTERMITTENT IV SETS

VASCULAR ACCESS PRELUDE SHEATH INTRODUCERS. Merit Medical s Innovative Family of Vascular Access Products A GREAT INTRODUCTION

Biofilm: Secret Refuge of the Microbial World

Ch 6. Microbial Nutrition and Growth

Antimicrobial Polymers in Medical Devices As Part of the Fight Against Healthcare-Acquired Infections (HAIs)

Hospital Acquired Infections The Problem

Disinfection of stainless steel in hospitals

Selenium nanoparticles and their utilization in scaffolds. Prof. RNDr. Vojtech Adam, Ph.D. Mgr. Dagmar Hegerova, Ph.D. Mendel University in Brno

Introduction [1] Introduction to the course; CEO and CLO

REFERENCE CAPACITY TIP SCALE BOX (UNITS) CASE (UNITS)

SilvaClean Antimicrobial Laundry Additive

EU MDR Deep Dive: GSPRs, Technical Docs, PMS. 19 JUNE 2018 ASQ RAPS MASSMEDIC Waltham Woods

Acoustic Pulse Thrombolysis Treatment

Small-Cap Research. ContraFect Corp. (CFRX-NASDAQ) CFRX: CF-301 Phase 1 Results Presented at ECCMID Conference UPDATE SUMMARY DATA ZACKS ESTIMATES

Anolytech Disinfection System

Anolytech Disinfection System

06 Vascular Access Safety Products 07 Vascular Access Conventional. p24 OPTIVA I.V. Catheters. p24 JELCO Striped I.V. Catheters

Draft Guidance for Industry and FDA Staff Premarket Notification [510(k)] Submissions for Medical Devices that Include Antimicrobial Agents

RESEARCH DIAGNOSTICS PREVENTION TREATMENT

FINAL PUBLISHABLE SUMMARY REPORT

MASTER IN PHARMACEUTICAL SCIENCES (Thesis Track)

Get the most out of Pure PRP

Material List by Procedure. The following lists are provided to ensure that the correct supplies are in place prior to the procedure.

Biofilm Based Wound Care Randall Wolcott MD

The first of its kind

8: IV/SQ Maintenance

The Optional ALN Vena Cava Filters

1-800-KAWASUMI ( ) P.O. Box Tampa, FL Phone: Fax:

COMPARING THE ANTIMICROBIAL ACTIVITY OF THE SEMCO 3A TOTAL ENERGY WHEEL WITH OTHER SELECTED ANTIMICROBIAL SURFACE TREATMENTS RESEARCH FINDINGS

LiquiBand Exceed Topical Skin Adhesive Summary of Effectiveness Data

STEM Car eer s: Metamor phosis of Medicine Coan Sharon Coan

**MATERIAL SAFETY DATA SHEET**

Study Title Antibacterial Efficacy of Bio-Care Technology's Non-Porous Test Substance

- Selection of Target Molecular for Drug Discovery by Verifications on the Validity of Target Candidates -

Flash Back Function - During the insertion of the cannula, blood flow is visualized by blood flash back in the hub of the cannula.

Question: What will be the Fee and Document requirement for medical devices and IVDs under grouping guidelines under Medical Devices Rules 2017?

NEW DRUGS FOR BAD BUGS The Innovative Medicines Initiative response to antimicrobial resistance

2120 Lab. Week 11. Experiments 13,14,21. Kirby Bauer, TDT, Chemicals

Working document QAS/ June 2011 RESTRICTED DRAFT FOR COMMENT

For special applications, we can also provide flexible and stiff nitinol guidewires with a longer and extra soft angled flexible safety tip.

UV STERILISATION & THE CASE FOR PREFILLED & PRELOADED DRUG DELIVERY SYSTEMS

TREAT SMARTER. ACHIEVE MORE. When Treating Thrombus

Peripheral Venous Catheter and Central venous catheter care : an IVN Approach. Nutcharee Jungvanichar RN, MBA

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

NO COPY FOSUN MEDICAL. enterprises in 2010 and it had been the largest taxpayer among Chinese private

The Optional ALN Vena Cava Filters

Optimizing Breast Pocket Irrigation: An in Vitro Study and Clinical Implications

Transcription:

Bactiguard Infection Protection BIP Central Venous Catheter For prevention of healthcare associated infections

Bactiguard benefits Reduced healthcare costs Reduced use of antibiotics Save lives Bloodstream infections Catheter related bloodstream infections (CRBSI), also known as Central Line Associated Bloodstream Infections (CLABSI), account for a large proportion of the costs related to healthcare associated infections (HAI) in patients using medical devices, such as central venous catheters (CVC) 1. These infections can lead to serious complications, causing patient suffering as well as increased mortality and healthcare costs. In addition, many of these infections are treated with antibiotics, which increase the risk of emergence and spread of multi-resistant microbes. WHO estimates that antimicrobial resistance is so serious that it threatens the achievements of modern medicine 2. Healthcare Associated infections 1 Other Surgical site 22% 17% Respiratory tract* 32% 15% 14% Urinary tract* Bloodstream* *Bactiguard products available The solution: BIP Central Venous Catheter To address these problems, Bactiguard has developed a central venous catheter, the BIP CVC, with Bactiguard coating that reduces the risk of microbial adhesion and colonization. Bactiguard coated CVCs have been shown to reduce catheterrelated infections in high-risk patients, when compared to uncoated CVCs 3. The Bactiguard Infection Protection (BIP) technology is based on applying a very thin noble metal coating, consisting of gold, palladium and silver, to medical devices. The Bactiguard coating is firmly bound to the surface of the device and reduces the adhesion and growth of microbes. Material BIP CVC is made of polyure thane and coated with the Bactiguard coating. Usage BIP CVC is used to administer drugs and intravenous solutions, sample blood, as well as for blood pressure monitoring. BIP CVC can be used up to 30 days. Environment The Bactiguard coating is environmentally friendly and requires no special procedures for handling, use or disposal. More than 150 million Bactiguard coated urinary catheters have been sold for patient use, with no reported adverse events related to the coating.

The Bactiguard Infection Protection (BIP) technology Preventing infections A few seconds A few hours A few days Medical device surfaces attract bacteria, which develop into a biofilm. Catheter related blood stream infections occur when there is an immune response to bacteria in the blood. Bacteria begin to adhere to the surface. Bacteria begin to multiply. When enough bacteria have developed, they form a biofilm. If they begin to disperse, there is an increased risk of infection. Uncoated surface The noble metals in the Bactiguard coating cause a galvanic effect, which prevents bacteria from adhering to the surface. Coated products demonstrate a reduced bacterial adhesion, which in turn prevents biofilm formation and subsequent infection. A few seconds Bacteria begin to adhere to the surface. A few hours Bactiguard coated catheter surface A few days Less bacteria adhere to the surface of the Bactiguard coated surface, preventing biofilm formation and subsequent infection. Gold Au Palladium Pd Silver Ag A galvanic effect is created due to the noble metals in the fluids Bacteria Galvanic effect The three noble metals in the Bactiguard coating gold, palladium and silver, cause a galvanic effect. This creates a micro current. The current prevents bacteria from adhering to the surface. Bactiguard compared to traditional releasing technologies 4 These technologies depend on release of toxic substances, such as silver ions, attacking the bacteria. Silver Ag Dying bacteria Silver ions are released from the surface, killing bacteria. Can cause tissue damage. 5 to 10 times thicker layer than a surface with Bactiguard coating. Becomes thinner over time due to release.

In Vitro/Ex Vivo Efficacy The reduction of microbial adhesion and colonization to device surfaces has been verified for clinically relevant microbial strains using an in vitro efficacy test. The in vitro test evaluates the adhesion of microorganisms to device surfaces. Example of results (Staphylocuccus aureus) are presented in the figures below 5. Less bacteria adhere to the Bactiguard coated surface and for those who adhere, further growth is expected to be suppressed, preventing biofilm formation and subsequent infection. Staphylocuccus aureus Microbe build-up without Bactiguard coating Microbe build-up with Bactiguard coating Less bacteria adhere to the Bactiguard coated surface Reduction in microbial adhesion to BIP CVC5 600000 Standard CVC catheter Bactiguard coated CVC catheter 500000 400000 CFU/cm2 300000 200000 100000 0 91% Pseudomonas aeruginosa 76% Coagulase negative Staphylococcus aureus 86% Staphylococcus aureus Average raw data from several batches of BIP CVC

TAT* relatively to blood control Clinically proven effective against bloodstream infections In a clinical study of Bactiguard coated central venous catheters it was concluded that the coating significantly reduced the incidence of infections by 52% (graph below). The investigation included 233 hematological oncology patients, 113 received standard uncoated catheters and 120 received Bactiguard coated catheters. Catheter related infection developed in 21% of patients with the standard catheter but in only 10% of the patients with the Bactiguard coated catheters 3. Biocompatible The Bactiguard coating has a strong biocompatibility profile. In ex-vivo experiments (graph below) with human blood, BIP CVC has showed improved blood compatibility properties in terms of lower risk of thrombosis compared to standard CVC. In the same study BIP CVC was also shown to be nonhemolytic compared to other coated CVCs 6. 45,0 40,0 Uncoated 35,0 BIP CVC Number of patient 30 Reduction in catheter related infections 30,0 25,0 20,0 p=0.02, significant Standard CVC catheter Bactiguard coated CVC catheter 15,0 10,0 20 5,0 0,0 Uncoated BIP CVC 10 *TAT= Thrombin Anti-Thrombin complex, depends on activation of coagulation and is used as marker for thrombotic risk Adapted from Vafa Homann et al. 2015 0 Catheter-related infection p=0.011 Adapted from Goldschmidt.et al. 1995 Local catheter infection p=0.232 Catheter-related bacteremia p=0.055 Additionally, in a clinical trial of Bactiguard coated CVC s (table below), data showed no increased risk for trombosis compared to the control group with uncoated CVC 7. Adapted from Goldschmidt H.et al. 1995 Tissue-friendly and safe technology The Bactiguard solution is unique, tissue friendly and safe for patient use. As opposed to coating technologies, which depend on the release of substances, which kill bacteria, e.g. large amounts of silver ions, chlorhexidine or antibiotics, the Bactiguard coating is neither toxic nor pharmacologic 5. To date, more than 150 million Bactiguard coated urinary catheters have been sold for patient use, with no reported adverse events related to the coating. Frequency of Catheter-Related Thrombosls Examined by Ultrasound Factor Standard Catheter (n = 113) Bactiguard Coated Catheter (n = 120) Visualization of thrombus 3 1 Absence of spontaneous flow 2 0 Total no. of catheter-related thromboses 3 1 Adapted from Table 2, Harter et al. 2002

References 1. Klevens RM et al, Public Health Rep. 2007 Mar-Apr;122(2):160 6 2. Kalra OP et al, J Glob Infect Dis. 2009 Jan;1(1):57 63 3. Goldschmidt H.et al., Zbl. Bakt.1995; 233: 215-223 4. Data on file 5. Data on file 6. Vafa Homann et al. 2015, J. Biomed. Mater. Res. Part B Appl. Biomater 7. Harter et al, Cancer. 94 (1):245-251 (2002)

Order information Product range BIP Central Venous Catheter Article number Size (Fr/Ch) Lumen Gauge (G) Length (cm) Introducer needle 1 Lumen EU-CVN-401-16-BIP 4 18G 16 Straight EU-CVN-401-20-BIP 4 18G 20 Straight EU-CVN-501-16-BIP 5 16G 16 Straight EU-CVN-501-20-BIP 5 16G 20 Straight EU-CVN-701-16-BIP 7 14G 16 Straight EU-CVN-701-20-BIP 7 14G 20 Straight EU-CVN-501-16Y-BIP 5 16G 16 Y-valve EU-CVN-501-20Y-BIP 5 16G 20 Y-valve EU-CVN-701-16Y-BIP 7 14G 16 Y-valve EU-CVN-701-20Y-BIP 7 14G 20 Y-valve 2 Lumen EU-CVN-402-06-BIP 4 22/22G 6 Straight EU-CVN-402-10-BIP 4 22/22G 10 Straight EU-CVN-402-16-BIP 4 22/22G 16 Straight EU-CVN-502-10-BIP 5 18/18G 10 Straight EU-CVN-502-16-BIP 5 18/18G 16 Straight EU-CVN-502-20-BIP 5 18/18G 20 Straight EU-CVN-702-16-BIP 7 16/16G 16 Straight EU-CVN-702-20-BIP 7 16/16G 20 Straight EU-CVN-702-30-BIP 7 16/16G 30 Straight EU-CVN-802-16-BIP 8,5 13/13G 16 Straight EU-CVN-802-20-BIP 8,5 13/13G 20 Straight EU-CVN-802-30-BIP 8,5 13/13G 30 Straight EU-CVN-502-10Y-BIP 5 18/18G 10 Y-valve EU-CVN-502-16Y-BIP 5 18/18G 16 Y-valve EU-CVN-502-20Y-BIP 5 18/18G 20 Y-valve EU-CVN-702-16Y-BIP 7 16/16G 16 Y-valve EU-CVN-702-20Y-BIP 7 16/16G 20 Y-valve EU-CVN-702-30Y-BIP 7 16/16G 30 Y-valve EU-CVN-802-16Y-BIP 8,5 13/13G 16 Y-valve EU-CVN-802-20Y-BIP 8,5 13/13G 20 Y-valve EU-CVN-802-30Y-BIP 8,5 13/13G 30 Y-valve 3 Lumen EU-CVN-503-08-BIP 5,5 20/22/22G 8 Straight EU-CVN-503-13-BIP 5,5 20/22/22G 13 Straight EU-CVN-503-30-BIP 5,5 20/22/22G 30 Straight EU-CVN-703-10-BIP 7 16/18/18G 10 Straight EU-CVN-703-16-BIP 7 16/18/18G 16 Straight EU-CVN-703-20-BIP 7 16/18/18G 20 Straight EU-CVN-703-30-BIP 7 16/18/18G 30 Straight EU-CVN-713-10-BIP 7 14/18/18G 10 Straight EU-CVN-713-16-BIP 7 14/18/18G 16 Straight EU-CVN-713-20-BIP 7 14/18/18G 20 Straight EU-CVN-713-30-BIP 7 14/18/18G 30 Straight Article number Contents BIP CVC-kit: Size (Fr/Ch) Central venous catheter J-guidewire (Nitinol), sized to catheter Introducer needle (Y-shape* or Straight) Dilator, size appropriate to catheter Scalpel with protective cover Luer-Lock syringe 5 ml The products are CE marked according to Medical Device Directive 93/42/EEC Lumen Gauge (G) Length (cm) EU-CVN-803-16-BIP 8,5 14/18/18G 16 Straight EU-CVN-803-20-BIP 8,5 14/18/18G 20 Straight EU-CVN-803-30-BIP 8,5 14/18/18G 30 Straight EU-CVN-703-10Y-BIP 7 16/18/18G 10 Y-valve EU-CVN-703-16Y-BIP 7 16/18/18G 16 Y-valve EU-CVN-703-20Y-BIP 7 16/18/18G 20 Y-valve EU-CVN-703-30Y-BIP 7 16/18/18G 30 Y-valve EU-CVN-713-10Y-BIP 7 14/18/18G 10 Y-valve EU-CVN-713-16Y-BIP 7 14/18/18G 16 Y-valve EU-CVN-713-20Y-BIP 7 14/18/18G 20 Y-valve EU-CVN-713-30Y-BIP 7 14/18/18G 30 Y-valve EU-CVN-803-16Y-BIP 8,5 14/18/18G 16 Y-valve EU-CVN-803-20Y-BIP 8,5 14/18/18G 20 Y-valve EU-CVN-803-30Y-BIP 8,5 14/18/18G 30 Y-valve 4 Lumen EU-CVN-804-16-BIP 8,5 14/16/18/18G 16 Straight EU-CVN-804-20-BIP 8,5 14/16/18/18G 20 Straight EU-CVN-804-30-BIP 8,5 14/16/18/18G 30 Straight EU-CVN-804-16Y-BIP 8,5 14/16/18/18G 16 Y-valve EU-CVN-804-20Y-BIP 8,5 14/16/18/18G 20 Y-valve EU-CVN-804-30Y-BIP 8,5 14/16/18/18G 30 Y-valve Guidewire advancer, for one hand use Suture wings and staples Clamp for extension tube Cannula holder Sterilization and storage; see packaging. Department pack = 10 pcs. Transport pack = 10 10 pcs. Size department pack W H D: 260 165 225 mm Introducer needle * Y-Valve needle allows for easy guidewire insertion while minimizing air embolism and backflow of blood

Phone +46 (0)8 440 58 80 Fax +46 (0)8 440 58 90 www.bactiguard.com info@bactiguard.com Visit: Alfred Nobels Allé 150 146 48 Tullinge Sweden Mail: Box 15, 146 21 Tullinge Sweden RMH021-C. 20160602 Phone +46 (0)8 440 58 80 Fax +46 (0)8 440 58 90 www.bactiguard.com info@bactiguard.com biporder@bactiguard.se